Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ligand Pharm (NQ: LGND ) 99.95 -1.40 (-1.38%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ligand Pharm < Previous 1 2 3 4 5 6 Next > Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy September 06, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference August 20, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Looking Into Ligand Pharmaceuticals's Recent Short Interest August 16, 2024 Via Benzinga Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review August 09, 2024 After Monday's panicked global sell-off, markets have calmed down. Via Investor's Business Daily Assessing Ligand Pharmaceuticals: Insights From 6 Financial Analysts July 30, 2024 Via Benzinga What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals June 28, 2024 Via Benzinga LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 August 06, 2024 LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts August 06, 2024 Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped. Via Investor's Business Daily Ligand Reports Second Quarter 2024 Financial Results August 06, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 July 23, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire 5 Best Short-Term Stocks to Consider Investing In July 10, 2024 Looking for the best short-term stocks? Explore our top picks and learn how to navigate the risks and opportunities in fast-paced stock trading. Via MarketBeat Ligand to Acquire APEIRON Biologics AG for $100 Million July 08, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Lifecore Biomedical Announces Cooperation Agreement with 22NW July 01, 2024 Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board From Lifecore Biomedical, Inc. Via GlobeNewswire Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years June 27, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults June 18, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Participate in Upcoming Investor Conferences May 23, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire 3 Magnificent Growth Stocks to Buy Hand Over Fist May 22, 2024 Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst. Via The Motley Fool Topics Economy Exposures Interest Rates 3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off May 20, 2024 With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation. Via InvestorPlace LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 May 07, 2024 LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Ligand Reports First Quarter 2024 Financial Results May 07, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement May 07, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Don't Overlook These Top Medical Stocks As Q1 Earnings Approach May 07, 2024 While the tech sector has led the Q1 earnings season, investors shouldn’t overlook these top medical stocks. To that point, the growth and expansion of Ligand Pharmaceuticals, Oscar Health, and... Via Talk Markets Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 April 23, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire 7 Small-Cap Stocks for the Thinking Speculator April 08, 2024 While these small-cap stocks may be miles away from Wall Street’s spotlight, they’re compelling enough to deliver some big surprises. Via InvestorPlace Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference April 08, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™ April 03, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference March 05, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 04, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Why Is Ligand Pharmaceuticals Stock Trading Higher Today? February 27, 2024 Ligand Pharmaceuticals beats Q4 2023 sales estimates at $28.1 million, with strong core Captisol and royalty figures. CEO Todd Davis highlights transformative 2023 and optimistic guidance for 2024. Via Benzinga Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session February 27, 2024 Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.